Hubei Biocause Heilen Pharmaceutical301211.SZValuation Analysis

As of Oct 19, 2026, Hubei Biocause Heilen Pharmaceutical (301211.SZ) trades at a P/E of 104.00x, P/B of 2.13x, P/S of 9.80x, and a dividend yield of 0.52%.
Longitudinal percentile comparison: P/E sits at the 72nd percentile over the trailing 10Y window (vs. 56th percentile over 3Y); P/B sits at the 27th percentile over the trailing 10Y window (vs. 34th percentile over 3Y); P/S sits at the 40th percentile over the trailing 10Y window (vs. 40th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 82nd percentile within its industry and the 81st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.52%, ranking at the 13th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 45.3 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Hubei Biocause Heilen Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.